Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic non-small cell lung cancer and a mutation causing MET exon 14 skipping, identified by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
Created a biomarker-directed option for this molecular subgroup under accelerated approval.
What research teams should watch
Confirm the assay can identify the relevant splice alteration and document how a negative plasma result is resolved.
PRIMARY RECORDS